Plasmonic MXene-based nanocomposites exhibiting photothermal therapeutic effects with lower acute toxicity than pure MXene.
Clicks: 230
ID: 11586
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
71.6
/100
230 views
184 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Here, we fabricated two plasmonic 2D TiCT-based nanocomposites (Au/MXene and Au/FeO/MXene) with similarly high anti-cancer photothermal therapy (PTT) capabilities, but with less in vivo toxicity than a pure MXene. Au/MXene was synthesized by in situ reduction of tetrachloroauric acid using NaBH on TiCT flakes. For targeted PTT, magnetic Au/FeO/MXene was synthesized via a reaction between freshly prepared magnetite FeO NPs and MXene solution, followed by in situ integration of gold nanoparticles (AuNPs). Morphological characterization by XRD, SEM, and TEM revealed the successful synthesis of Au/MXene and Au/FeO/MXene. Both new composites exhibited a significant in vitro dose-dependent PTT effect against human breast cancer cells MCF7. Interestingly, in vivo acute toxicity assays using zebrafish embryos indicated that Au/MXene and Au/FeO/MXene had less embryonic mortality (LC ≫ 1000 µg/mL) than pure MXene (LC=257.46 µg/mL). Our new Au/MXene and Au/FeO/MXene nanocomposites could be safer and more suitable than the pure MXene for biomedical applications, especially when targeted PTT is warranted.Reference Key |
hussein2019plasmonicinternational
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | Hussein, Essraa A;Zagho, Moustafa M;Rizeq, Balsam R;Younes, Nadin N;Pintus, Gianfranco;Mahmoud, Khaled A;Nasrallah, Gheyath K;Elzatahry, Ahmed A; |
Journal | international journal of nanomedicine |
Year | 2019 |
DOI | 10.2147/IJN.S202208 |
URL | |
Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.